Eplontersen trial fails to meet primary endpoint in transthyretin-mediated amyloid cardiomyopathy

1 month ago 10
The CARDIO-TTRansform proceedings investigating eplontersen successful patients with transthyretin-mediated amyloid cardiomyopathy did not conscionable its superior efficacy endpoint, according to results presented successful a Hot Line league astatine ESC Congress 2026.
Read Entire Article